Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …

Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC)
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …

The use of advanced molecular profiling to direct the use of targeted therapy, such as
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …

Purpose Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged
non–small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in patients with brain …

Brain metastases (BM) are the most commonly diagnosed type of central nervous system
tumor in the United States. Estimates of the frequency of BM vary significantly, as there is no …

Introduction Brain metastases (BM) are common in non-small-cell lung cancer (NSCLC).
However, the baseline incidence and evolution of BM over time in oncogene-driven …

Purpose Cancer spread to the central nervous system (CNS) often is diagnosed late and is
unresponsive to therapy. Mechanisms of tumor dissemination and evolution within the CNS …

Brain metastases are one of the most common neurologic complications of cancer. The
incidence is 9%–17% based on various studies, although the exact incidence is thought to …

Introduction Activating mutations in the epidermal growth factor receptor gene (EGFR)
predict for prolonged progression-free survival in patients with advanced non–small cell …